Cargando…

Triple-negative breast cancer: promising prognostic biomarkers currently in development

INTRODUCTION: Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer associated with poor prognosis and limited treatment options. Validated prognostic and predictive biomarkers are needed to guide treatment decisions and prognostication. AREAS COVERED: In this review, we discus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sukumar, Jasmine, Gast, Kelly, Quiroga, Dionisia, Lustberg, Maryam, Williams, Nicole
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174647/ https://www.ncbi.nlm.nih.gov/pubmed/33198517 http://dx.doi.org/10.1080/14737140.2021.1840984

Ejemplares similares

Sacituzumab govitecan: ascending the treatment algorithm in triple negative breast cancer
por: Rozenblit, Mariya, et al.
Publicado: (2022)

TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer
por: Elbaz, Mohamad, et al.
Publicado: (2016)

Development of an immune-related prognostic biomarker for triple-negative breast cancer
por: Zhang, Yan, et al.
Publicado: (2022)

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges
por: Wang, Xiaoxiao, et al.
Publicado: (2023)

Endocan as a prognostic biomarker of triple-negative breast cancer
por: Sagara, Atsunobu, et al.
Publicado: (2016)

Exploring specific prognostic biomarkers in triple-negative breast cancer
por: Bao, Chang, et al.
Publicado: (2019)

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Johnson, Kai Conrad Cecil, et al.
Publicado: (2023)

The clinical promise of immunotherapy in triple-negative breast cancer
por: Vikas, Praveen, et al.
Publicado: (2018)

RUNX2: a prognostic biomarker for triple-negative breast cancer?
Publicado: (2014)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher, Brett, et al.
Publicado: (2016)

Panoptic Overview of Triple-Negative Breast Cancer in Nigeria: Current Challenges and Promising Global Initiatives
por: Wright, Nikita, et al.
Publicado: (2018)

Long Non Coding RNA in Triple Negative Breast Cancer: A Promising Biomarker in Tumorigenesis
por: Nandagopal, Srividhya, et al.
Publicado: (2023)

Delay Discounting as a Potential Therapeutic Target for Weight Loss in Breast Cancer Survivors
por: Sukumar, Jasmine S., et al.
Publicado: (2022)

Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
por: Ryu, Won-Ji, et al.
Publicado: (2021)

TTK is a favorable prognostic biomarker for triple-negative breast cancer survival
por: Xu, Qianqian, et al.
Publicado: (2016)

CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

CCR5 is a prognostic biomarker and an immune regulator for triple negative breast cancer
por: Wang, Xin, et al.
Publicado: (2021)

Genome Instability-Derived Genes Are Novel Prognostic Biomarkers for Triple-Negative Breast Cancer
por: Guo, Maoni, et al.
Publicado: (2021)

Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods
por: Porta, Francesca Maria, et al.
Publicado: (2023)

Characterization of ceRNA network to reveal potential prognostic biomarkers in triple-negative breast cancer
por: Song, Xiang, et al.
Publicado: (2019)

Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers
por: Liu, Yiduo, et al.
Publicado: (2021)

The roles of small extracellular vesicles as prognostic biomarkers and treatment approaches in triple-negative breast cancer
por: Zhou, Yueyuan, et al.
Publicado: (2022)

Identification of MTHFD2 as a prognostic biomarker and ferroptosis regulator in triple-negative breast cancer
por: Zhang, Hao, et al.
Publicado: (2023)

Triple negative breast cancer – prognostic factors and survival
por: Ovcaricek, Tanja, et al.
Publicado: (2010)

Prognostic values of EDNRB in triple-negative breast cancer
por: Liu, Shaoqing, et al.
Publicado: (2020)

Standard of Care and Promising New Agents for Triple Negative Metastatic Breast Cancer
por: Mancini, Patrizia, et al.
Publicado: (2014)

Current approaches in treatment of triple-negative breast cancer
por: Wahba, Hanan Ahmed, et al.
Publicado: (2015)

miRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer
por: Mathe, Andrea, et al.
Publicado: (2015)

Immune-related biomarkers in triple-negative breast cancer
por: Zhang, Juan, et al.
Publicado: (2021)

LncRNAs as new biomarkers to differentiate triple negative breast cancer from non-triple negative breast cancer
por: Lv, Mingming, et al.
Publicado: (2016)

Nectin-4 Expression Is an Independent Prognostic Biomarker and Associated With Better Survival in Triple-Negative Breast Cancer
por: Zeindler, Jasmin, et al.
Publicado: (2019)

Prognostic Effect of Microenvironment Phenotype in Triple-Negative Breast Cancer: Biomarker Analysis of a Prospective Trial
por: Zhu, Si-Yuan, et al.
Publicado: (2021)

ARNTL2 is a Prognostic Biomarker and Correlates with Immune Cell Infiltration in Triple-Negative Breast Cancer
por: Wang, Xiaoyu, et al.
Publicado: (2021)

Circular RNA: A potential diagnostic, prognostic, and therapeutic biomarker for human triple-negative breast cancer
por: Tian, Tian, et al.
Publicado: (2021)

Granzyme B Expression in the Tumor Microenvironment as a Prognostic Biomarker for Patients with Triple-Negative Breast Cancer
por: Mizoguchi, Kimihisa, et al.
Publicado: (2023)

SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer
por: Zhu, Youzhi, et al.
Publicado: (2023)

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer
por: Rhee, Jiyoung, et al.
Publicado: (2008)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021)

Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer
por: Mezi, Silvia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5plobb2b4c0raja8j8ug7oev3o